1998•PubMedRequires access

[Diagnostic approach to the anemic cancer patient].

Massimo Aglietta

Open publisher page 1 citations

Abstract

The anemia of the neoplastic patient can be: the first sign of a yet unknown neoplasia; a sign of progressive disease; an effect of therapy. The hemochromocytometric will define if the anemia is normocytic, microcytic or macrocytic. The reticulocyte counts will define the degree of marrow erythrocyte production. Thus specific algorithms could be used for trying to define the origin of the anemia. On the basis of the patient history, physical examination and other ad hoc exams it will be possible to determine the origin of the anemia keeping into mind the types of anemia of the neoplastic patients: anemia due to damage of the erythron as a consequence of chemotherapy; anemia of chronic disorders with a multiple pathogenesis. A decreased EPO production is often relevant; anemia due to renal damage (platinum compounds, anfotericin B) with decreased EPO production. A correct approach will allow the identification of the cause of the anemia and a correct treatment. Serum EPO determination can be useful to decide for EPO administration.

About this research paper

What this paper is about

The anemia of the neoplastic patient can be: the first sign of a yet unknown neoplasia; a sign of progressive disease; an effect of therapy. The hemochromocytometric will define if the anemia is normocytic, microcytic or macrocytic. The reticulocyte counts will define the degree of marrow erythrocyte production. Thus specific algorithms could be used for trying to define the origin of the anemia. On the basis of the patient history, physical examination and other ad hoc exams it will be possible to determine the origin of the anemia keeping into mind the types of anemia of the neoplastic patients: anemia due to damage of the erythron as a consequence of chemotherapy; anemia of chronic disorders with a multiple pathogenesis. A decreased EPO production is often relevant; anemia due to renal damage (platinum compounds, anfotericin B) with decreased EPO production. A correct approach will allow the identification of the cause of the anemia and a correct treatment. Serum EPO determination can be useful to decide for EPO administration.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The anemia of the neoplastic patient can be: the first sign of a yet unknown neoplasia; a sign of progressive disease; an effect of therapy. The hemochromocytometric will define if the anemia is normocytic, microcytic or macrocytic. The reticulocyte counts will define the degree of marrow erythrocyte production. Thus specific algorithms could be used for trying to define the origin of the anemia. On the basis of the patient history, physical examination and other ad hoc exams it will be possible to determine the origin of the anemia keeping into mind the types of anemia of the neoplastic patients: anemia due to damage of the erythron as a consequence of chemotherapy; anemia of chronic disorders with a multiple pathogenesis. A decreased EPO production is often relevant; anemia due to renal damage (platinum compounds, anfotericin B) with decreased EPO production. A correct approach will allow the identification of the cause of the anemia and a correct treatment. Serum EPO determination can be useful to decide for EPO administration.

Key concepts: Macrocytic anemia, Anemia, Microcytic anemia, Medicine, Reticulocyte, Anemia of chronic disease, Disease, Cancer

Related papers

Back to paper searchBrowse research topicsOriginal source
[Diagnostic approach to the anemic cancer patient]. — Research Paper | ScholarLens